Prevalence of sero-markers and non-invasive assessment of liver cirrhosis in patients with Hepatitis B virus infection in Freetown, Sierra Leone: a cross-sectional study
- PMID: 34372775
- PMCID: PMC8353767
- DOI: 10.1186/s12876-021-01892-5
Prevalence of sero-markers and non-invasive assessment of liver cirrhosis in patients with Hepatitis B virus infection in Freetown, Sierra Leone: a cross-sectional study
Abstract
Background: Hepatitis B virus (HBV) is a major global health problem. Although sub-Saharan Africa has a high proportion of the global burden of HBV, the epidemiology and clinical features of HBV in this region are poorly characterized, and access to diagnostic and treatment services remain limited.
Methods: We conducted a retrospective study of HBV-infected children and adults of all age groups who were evaluated at public and private health facilities in Freetown, Sierra Leone between January 2017 and January 2019. We assessed their clinical presentation, HBV sero-markers, stages of liver disease, prevalence of cirrhosis by non-invasive tools, and the proportion of treatment eligible patients using the criteria recommended by the World Health Organization's 2015 treatment guidelines for HBV. Logistic regression was used to identify predictors of liver cirrhosis.
Results: 163 HBV patients included in the study, with mean age 32.6 years and 65.0% (106) being males. Most (84.0%) were asymptomatic at presentation. The majority (69.9%) were classified as having HBeAg-negative chronic infection (or inactive HBsAg carrier phase), 24.5% were in the HBeAg-negative immune active phase, 3.1% had HBeAg positive hepatitis, and 2.5% were HBsAg negative. The median Aspartate aminotransferase to Platelet Ratio (APRI) and Fibrosis-4 (FIB-4) scores were 0.37 and 0.80, respectively. The prevalence of cirrhosis was 7.6% and 6.2%, estimated by the APRI and FIB-4 scores, respectively. About 20.0% of patients were eligible for treatment with antiviral agents. Based on APRI scores, the presence of any symptom [adjusted odds ratio (aOR) 20.0, 95% confidence interval (CI) (4.1-85.9); p < 0.001], elevated direct bilirubin [aOR 12.1, 95% CI (1.9-63.0); p = 0.003], and elevated total bilirubin [aOR 16.1, 95% CI (3.2-80.8); p = 0.001] were independent predictors of cirrhosis.
Conclusion: Although most patients with HBV infection were asymptomatic, the prevalence of liver cirrhosis and proportion of patients requiring antiviral treatment were substantial. This small study from a hyperendemic setting in Sierra Leone suggests that routine population-based screening may increase early detection and linkage of HBV patients to care before development of complications. Larger studies are needed to confirm our findings.
Keywords: Cirrhosis; HBV; Liver fibrosis; Resource-limited settings; Sierra Leone.
© 2021. The Author(s).
Conflict of interest statement
The authors declare no competing interests.
The authors declare that they have no competing interest.
Similar articles
-
Prevalence and associated knowledge of hepatitis B infection among healthcare workers in Freetown, Sierra Leone.BMC Infect Dis. 2018 Jul 9;18(1):315. doi: 10.1186/s12879-018-3235-1. BMC Infect Dis. 2018. PMID: 29986658 Free PMC article.
-
Prevalence of hepatitis B surface antigen and serological markers of other endemic infections in HIV-infected children, adolescents and pregnant women in Sierra Leone: A cross-sectional study.Int J Infect Dis. 2021 Jan;102:45-52. doi: 10.1016/j.ijid.2020.09.1459. Epub 2020 Sep 28. Int J Infect Dis. 2021. PMID: 33002619
-
Prevalence and viral suppression of hepatitis B virus infection among people living with HIV on antiretroviral therapy in Sierra Leone.Sex Transm Infect. 2024 Jul 26;100(5):264-270. doi: 10.1136/sextrans-2023-056042. Sex Transm Infect. 2024. PMID: 38789266
-
Prevalence of liver cirrhosis in individuals with hepatitis B virus infection in sub-Saharan Africa: Systematic review and meta-analysis.Liver Int. 2021 Apr;41(4):710-719. doi: 10.1111/liv.14744. Epub 2020 Dec 12. Liver Int. 2021. PMID: 33220137 Free PMC article.
-
Prevalence of Chronic Hepatitis B Virus Infection in Sierra Leone, 1997-2022: A Systematic Review and Meta-Analysis.Am J Trop Med Hyg. 2023 May 22;109(1):105-114. doi: 10.4269/ajtmh.22-0711. Print 2023 Jul 5. Am J Trop Med Hyg. 2023. PMID: 37217165 Free PMC article.
Cited by
-
Measuring Stigma Associated with Hepatitis B Virus Infection in Sierra Leone: Validation of an Abridged Berger HIV Stigma Scale.medRxiv [Preprint]. 2023 Feb 18:2023.02.17.23286086. doi: 10.1101/2023.02.17.23286086. medRxiv. 2023. Update in: J Viral Hepat. 2023 Jul;30(7):621-629. doi: 10.1111/jvh.13838. PMID: 36824916 Free PMC article. Updated. Preprint.
-
Measuring stigma associated with hepatitis B virus infection in Sierra Leone: Validation of an abridged Berger HIV stigma scale.J Viral Hepat. 2023 Jul;30(7):621-629. doi: 10.1111/jvh.13838. Epub 2023 Apr 21. J Viral Hepat. 2023. PMID: 37084170 Free PMC article.
-
Chronic hepatitis B virus infection in Eastern Ethiopia: Clinical characteristics and determinants of cirrhosis.World J Hepatol. 2024 Jul 27;16(7):995-1008. doi: 10.4254/wjh.v16.i7.995. World J Hepatol. 2024. PMID: 39086536 Free PMC article.
-
Prevalence of hepatitis B virus infection and treatment eligibility in Lesotho, Southern Africa: a population-based cross-sectional study with case-based follow-up.BMJ Public Health. 2024 Nov 29;2(2):e001195. doi: 10.1136/bmjph-2024-001195. eCollection 2024 Dec. BMJ Public Health. 2024. PMID: 40018538 Free PMC article.
-
Non-invasive assessment of hepatic fibrosis among patients with chronic hepatitis B virus infection in three tertiary hospitals in Nigeria.SAGE Open Med. 2024 Aug 7;12:20503121241264313. doi: 10.1177/20503121241264313. eCollection 2024. SAGE Open Med. 2024. PMID: 39119474 Free PMC article.
References
-
- WHO 2018. WHO Global hepatitis report, 2017. Available from: https://www.who.int/hepatitis/publications/global-hepatitis-report2017/en/.
-
- Progress report on HIV, viral hepatitis and sexually transmitted infections 2019. Accountability for the global health sector strategies, 2016–2021. WHO Geneva 2019. Available from: https://www.who.int/hiv/strategy2016-2021/progress-report-2019/en/.
-
- WHO 2016. Global health sector strategy on viral hepatitis 2016–2021. Available from: https://apps.who.int/iris/bitstream/handle/10665/246177/WHO-HIV-2016.06-...
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
